This is the first study in predictive testing for NSCLC and metastatic colorectal cancer (mCRC) to include this extent of longitudinal scheme data, as well as KRAS proto‐oncogene GTPase (KRAS) and NRAS proto‐oncogene GTPase (NRAS) variants besides EGFR variants. This evidence concerns the gene KRAS and non-small cell lung carcinoma.